BioMarin Stock Outlook Brightens After Patent Settlement and Strategic Acquisition

Key Facts

1Jefferies analyst raised BioMarin's price target to $105, signaling a potential 60% upside.

2BioMarin reached a patent settlement with Ascendis Pharma, securing 20% royalties on U.S. sales of the drug Yuviwel.

3The company acquired Alesta Therapeutics for $275 million to expand its rare disease pipeline.

In a move reflecting optimism within the specialized biotechnology sector, Jefferies has raised its price target for BioMarin to $105, suggesting a potential 60% upside. This upgrade follows the company's global patent settlement with Ascendis Pharma, which secures BioMarin a 20% royalty on U.S. sales of the drug Yuviwel, alongside 18% royalties in the EU, Brazil, and South Korea through May 2030.

BioMarin further strengthened its rare disease market position by acquiring Alesta Therapeutics for $275 million, a strategic acquisition aimed at adding a potential oral therapy for Hypophosphatasia to its pipeline. According to analyst reports, these new royalty streams and pipeline expansions support the long-term financial stability and growth of the company, which holds a market capitalization of approximately $12.7 billion.

While current price data for BioMarin is unavailable as of the close on August 31, 2026, investors are focused on the company's ability to integrate new assets and convert agreed royalties into tangible returns. In a broader context, recent U.S. data showed GDP growth at 1.5% for the quarter, a factor that may influence investor sentiment toward defensive sectors like healthcare.